Intravitreal ranibizumab for myopic choroidal neovascularization: Factors predictive of visual outcome and need for retreatment

American Journal of Ophthalmology

Volumn 151, Issue 3, 2011, Pages 529-534

  Calvo Gonzalez, Cristina ^a   Reche Frutos, Juan ^a   Donate, Juan ^a   Fernandez Perez, Cristina ^a   Garcia Feijoo, Julian ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MALE; MIDDLE AGED; MYOPIA; PROSPECTIVE STUDIES; RETREATMENT; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 79951808909     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.09.021     Document Type: Article

References (18)

1. Cohen SY, Laroche A, Leguen Y, et al. Ethiology of choroidal neovascularization in young patients. Ophthalmology 1996;103(8):1241-1244. (Pubitemid 26282507)
2. Blinder KJ, Blumenkranz MS, Bressler SB, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathological myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110(4):667-673.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431. (Pubitemid 44511557)
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432- 1444. (Pubitemid 44511558)
5. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355(14):1409-1412. (Pubitemid 44511554)
6. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114(12):2179-2182. (Pubitemid 350181137)
7. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147(1):94-100.
8. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147(1):84-93.
9. Konstantinidis L, Mantel I, Zografos L, Ambresin A. Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal Graefes Arch Clin Exp Ophthalmol 2009;247(11):1567-1569.
10. Silva RM, Ruiz-Moreno JM, Rosa P. et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12- months results. Retina 2010;30(3):407-412.
11. Monés JM, Amselem L, Serrano A, Garcia M, Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye 2009;23(6):1275-1280.
12. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009;29(6):750-756.
13. Lalloum F, Souied EH, Bastuji-Garin S, et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010;30(3):399-406.
14. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-elated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148(1):43-58.
15. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003;110(7):1297-1305. (Pubitemid 36842462)
16. Krebs I, Binder S, Stolba U, Glittenberg C, Brannath W, Goll A. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 2005;140(3):416-425.
17. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006;142(1):95-104.
18. Hayashi K, Ohno-Matsui K, Yoshida T, et al. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2005;243(1):13-19.